MX2009004986A - Metodos de tratamiento de anemia hemolitica. - Google Patents

Metodos de tratamiento de anemia hemolitica.

Info

Publication number
MX2009004986A
MX2009004986A MX2009004986A MX2009004986A MX2009004986A MX 2009004986 A MX2009004986 A MX 2009004986A MX 2009004986 A MX2009004986 A MX 2009004986A MX 2009004986 A MX2009004986 A MX 2009004986A MX 2009004986 A MX2009004986 A MX 2009004986A
Authority
MX
Mexico
Prior art keywords
methods
hemolytic anemia
treating hemolytic
treating
complement
Prior art date
Application number
MX2009004986A
Other languages
English (en)
Spanish (es)
Inventor
Russell P Rother
Leonard Bell
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2009004986A publication Critical patent/MX2009004986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2009004986A 2006-11-08 2007-11-08 Metodos de tratamiento de anemia hemolitica. MX2009004986A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/595,118 US20070116710A1 (en) 2004-02-03 2006-11-08 Methods of treating hemolytic anemia
PCT/US2007/023623 WO2008069889A2 (en) 2006-11-08 2007-11-08 Methods of treating hemolytic anemia

Publications (1)

Publication Number Publication Date
MX2009004986A true MX2009004986A (es) 2009-05-21

Family

ID=39326944

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004986A MX2009004986A (es) 2006-11-08 2007-11-08 Metodos de tratamiento de anemia hemolitica.

Country Status (10)

Country Link
US (1) US20070116710A1 (enExample)
EP (1) EP2089058A2 (enExample)
JP (1) JP2010509338A (enExample)
KR (1) KR20090076960A (enExample)
AU (1) AU2007328435B2 (enExample)
BR (1) BRPI0718830A2 (enExample)
CA (1) CA2669735A1 (enExample)
IL (1) IL198320A0 (enExample)
MX (1) MX2009004986A (enExample)
WO (1) WO2008069889A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007225044C1 (en) 2006-03-15 2018-03-29 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
KR101463631B1 (ko) 2006-03-31 2014-11-19 추가이 세이야쿠 가부시키가이샤 항체의 혈중 동태를 제어하는 방법
HUE026042T2 (en) 2006-10-10 2016-05-30 Regenesance B V Complement inhibition for improved nerve regeneration
AU2008303775A1 (en) * 2007-09-24 2009-04-02 Noxxon Pharma Ag C5a binding nucleic acids
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
CN101977603A (zh) * 2008-01-29 2011-02-16 细胞基因公司 使用免疫调节化合物来调节cd59水平的方法
US20110111406A1 (en) 2008-04-11 2011-05-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
PL2328616T3 (pl) * 2008-08-05 2015-10-30 Novartis Ag Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5
BRPI0921237A2 (pt) * 2008-11-10 2015-09-22 Alexion Pharma Inc métodos e composições para o tratamento de distúrbios associados ao complemento
WO2011057250A1 (en) 2009-11-09 2011-05-12 Alexion Pharmaceuticals, Inc. Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
WO2012073992A1 (ja) 2010-11-30 2012-06-07 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
AU2012356170B2 (en) 2011-12-21 2016-06-16 Novartis Ag Compositions and methods for antibodies targeting Factor P
PT2802660T (pt) 2012-01-10 2020-04-21 Aptarion Biotech Ag Novos ácidos nucleicos que se ligam a c5a
EP3750914A1 (en) * 2013-09-16 2020-12-16 Children's Hospital Medical Center Compositions and methods for treatment of hsct-associated thrombotic microangiopathy
AR103162A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos anti-c5 y métodos para su uso
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
EP3247723A1 (en) 2015-01-22 2017-11-29 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
WO2016200627A1 (en) 2015-06-09 2016-12-15 Children's Hospital Medical Center Dosing algorithm for complement inhibitor
KR102667023B1 (ko) 2016-06-14 2024-05-21 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
IT201600121482A1 (it) * 2016-11-30 2018-05-30 Univ Degli Studi Di Verona Fattore H per l’uso nel trattamento e/o prevenzione della formazione di eterotrombi in pazienti affetti da anemia falciforme
TW202412841A (zh) 2017-01-31 2024-04-01 日商中外製藥股份有限公司 抗c5抗體在製造用於治療或預防c5相關疾病的醫藥組合物之用途
EP3717004A4 (en) 2017-12-01 2021-12-01 Children's Hospital Medical Center COMPOSITIONS FOR BLOCKING INTERERONS AND THEIR METHODS OF USE
EP3724226A1 (en) 2017-12-13 2020-10-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
US20190247560A1 (en) 2018-02-13 2019-08-15 Gambro Lundia Ab Extracorporeal devices and methods of treating complement factor related diseases
SMT202400271T1 (it) 2018-08-01 2024-07-09 Chugai Pharmaceutical Co Ltd Composizione farmaceutica per l’uso nel trattamento o nella prevenzione di una patologia correlata a c5
CA3144921A1 (en) 2019-07-31 2021-02-04 F. Hoffmann-La Roche Ag Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
TWI886140B (zh) 2019-07-31 2025-06-11 瑞士商赫孚孟拉羅股份公司 藉由使用抗c5抗體克羅伐單抗（crovalimab）之治療或預防c5相關疾病之劑量及投藥療程
US20230416344A1 (en) 2020-04-16 2023-12-28 Alexion Pharmaceuticals, Inc. Methods for treating a complement mediated disorder caused by viruses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686100A (en) * 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
US5135916A (en) * 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
ATE414720T1 (de) * 2000-12-05 2008-12-15 Alexion Pharma Inc Rationell entworfene antikörper
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease

Also Published As

Publication number Publication date
WO2008069889A3 (en) 2008-08-07
IL198320A0 (en) 2011-08-01
AU2007328435A1 (en) 2008-06-12
AU2007328435B2 (en) 2013-03-07
KR20090076960A (ko) 2009-07-13
WO2008069889A9 (en) 2008-09-18
US20070116710A1 (en) 2007-05-24
CA2669735A1 (en) 2008-06-12
EP2089058A2 (en) 2009-08-19
WO2008069889A2 (en) 2008-06-12
JP2010509338A (ja) 2010-03-25
BRPI0718830A2 (pt) 2014-02-04

Similar Documents

Publication Publication Date Title
MX2009004986A (es) Metodos de tratamiento de anemia hemolitica.
WO2005074607A3 (en) Method of treating hemolytic disease
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
NO20083153L (no) Kjemiske forbindelser
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
SG170813A1 (en) New compounds
WO2007140002A3 (en) Method for treating non-hodgkin's lymphoma
MX2008007307A (es) Granulos/capsulas modificados que contienen ingrediente activo.
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
TW200716624A (en) Compounds for modulating TRPV3 function
UA90209C2 (ru) Фунгицидная композиция, способ борьбы с заболеваниями полезных растений и способ защиты товаров
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
SG10201407388XA (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
TW200714283A (en) Method and composition for treating peripheral vascular diseases
MX2010006823A (es) Metodos para el tratamiento de la gota.
ATE488232T1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
EP2425849A3 (en) Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
EA200601766A1 (ru) Производные имидазола
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal